Skip to content
value.today

Chimerix Inc.

Total raised
$61 M
2 rounds on record
Latest round
$45 M
Feb 2011
First round on record
Jul 2009
Today
Private
No later event on record

Funding rounds

2 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Chimerix Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jul 2019$35 MIssued in a merger or acquisition$10 to $50 million

Chimerix Inc.: Private sale, Jul 2019

Investors in this round

1 investor had bought by the notice of Jul 31, 2019: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 24 investors are named for Chimerix Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$35 M of $35 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
$5 million to $25 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Heather W. Knight-Trent · Executive Officer · Vice President of Regulatory Affairs
  • Michael A. Alrutz · Executive Officer · Senior Vice President, General Counsel and Corporate Secretary
  • Mike Andriole · Executive Officer · Chief Business and Financial Officer
  • Mike Sherman · Executive Officer, Director · Chief Executive Officer and President
  • Odin W. Naderer · Executive Officer · Vice President, Clinical Pharmacology and Translational Medicine
  • Randall A. Lanier · Executive Officer · Chief Science Officer
  • Roy W. Ware · Executive Officer · Chief Manufacturing and Technology Officer
  • W. Garrett Nichols · Executive Officer · Chief Medical Officer
  • Catherine L. Gilliss · Director
  • Edward F. Greissing, Jr. · Director
  • Fred A. Middleton · Director
  • James M. Daly · Director
  • Martha J. Demski · Director
  • Patrick F. Machado · Director
  • Robert J. Meyer · Director
  • Ronald C. Renaud, Jr · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On a merger: “The shares of common stock were issued in connection with the license of intellectual property assets.”

Signed by Michael Alrutz, SVP, General Counsel & Corporate Secretary. Source: SEC Form D, newest notice filed Jul 31, 2019. Read the notice at the SEC.

equitySEC
Feb 2011$45 MNo. 2$10 to $50 million

Chimerix Inc.: Raise no. 2, Feb 2011

Investors in this round

21 investors had bought by the notice of Feb 15, 2011: 21 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 24 investors are named for Chimerix Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$45 M of $69 M offered; $24 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • George I. Painter, Ph.D · Executive Officer, Director
  • Gwendolyn P. Painter, M.D., MPH · Executive Officer
  • Kenneth I. Moch · Executive Officer, Director
  • Arthur M. Pappas · Director
  • Farah P. Champsi · Director
  • James M. Niedel · Director
  • Martha J. Demski · Director
  • Seth A. Rudnick, M.D. · Director
  • Timothy J. Wollaeger · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Includes approximately $13,749,982.86 receivable by the Company upon the exercise of Warrants to purchase shares of the Company's Series F Preferred Stock, assuming no cashless exercise. Such Warrants have not yet been exercised.”

Signed by Jason L. Kent, Assistant Secretary. Source: SEC Form D, newest notice filed Feb 15, 2011. Read the notice at the SEC.

equity, optionsSEC
Jul 2009$16 MNo. 1$10 to $50 million

Chimerix Inc.: Raise no. 1, Jul 2009

Investors in this round

21 investors had bought by the notice of Aug 7, 2009: 21 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 24 investors are named for Chimerix Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$16 M of $16 M offered; $0 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • George Painter, Ph.D. · Executive Officer, Director
  • Kenneth I. Moch · Executive Officer
  • Merrick Almond, Ph.D. · Executive Officer
  • Rosemary O'Mahony, Ph.D. · Executive Officer
  • Edward E. Penhoet, Ph.D. · Director
  • Graham K. Crooke, M.B.B.S. · Director
  • Martha J. Demski · Director
  • Seth A. Rudnick, M.D. · Director
  • Timothy J. Wollaeger · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by George Painter, Ph.D., President and Chief Executive Officer. Source: SEC Form D, newest notice filed Aug 7, 2009. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Chimerix Inc. had revenue between $5 million and $25 million when it filed its newest notice of a funding round (Jul 2019).

    SEC Form D (revenue range) · Jul 2019

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jul 2019

Products and services#

No products or services on record: the address on record now leads to another company's site.

Investors#

24 named in official filings. Open an investor to see everything it has backed.

Investors in Chimerix Inc.
InvestorKindAmountRoundRoleSource
Alta Biopharma Partners III Gmbh & Co Beteiligungs KGFund or asset managernot statednot statedHeld Series D, E and F preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Alta Biopharma Partners III LPFund or asset managernot statednot statedHeld Series D, E and F preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Alta Embarcadero Biopharma Partners III LLCFund or asset managernot statednot statedHeld Series D, E and F preferred stock, 10% owner (Form 3, 2013)SEC Form 3
A.M. Pappas Life Science Ventures III, L.P.Venture capitalnot statednot statedHeld Series F preferred stock, 10% owner (Form 3, 2013)SEC Form 3
A.M. Pappas Life Science Ventures IV LPVenture capitalnot statednot statedHeld Series F preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Canaan Partners VII LLCFund or asset managernot statednot statedHeld Series D, E and F preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Canaan VII L.P.Fund or asset managernot statednot statedHeld Series D, E and F preferred stock, 10% owner (Form 3, 2013)SEC Form 3
New Leaf Venture Associates II, L.P.Venture capitalnot statednot statedHeld Series F preferred stock, 10% owner (Form 3, 2014)SEC Form 3
New Leaf Venture Management II, L.L.C.Venture capitalnot statednot statedHeld Series F preferred stock, 10% owner (Form 3, 2014)SEC Form 3
New Leaf Ventures II, L.P.Venture capitalnot statednot statedHeld Series F preferred stock, 10% owner (Form 3, 2014)SEC Form 3
PV III CEO Fund, L.P.Fund or asset managernot statednot statedHeld Series F preferred stock, 10% owner (Form 3, 2013)SEC Form 3
PV IV CEO Fund, L.P.Fund or asset managernot statednot statedHeld Series F preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Sanderling V Beteiligungs Gmbh & Co KGCompanynot statednot statedHeld Series A, B, B-1, C, D, E and F preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Sanderling V Biomedical Co Investment Fund LPFund or asset managernot statednot statedHeld Series A, B, B-1, C, D, E and F preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Sanderling V Biomedical LPFund or asset managernot statednot statedHeld Series A, B, B-1, C, D, E and F preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Sanderling Venture Partners V Co Investment Fund, LPVenture capitalnot statednot statedHeld Series A, B, B-1, C, D, E and F preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Sanderling Venture Partners VI Co Investment Fund LPVenture capitalnot statednot statedHeld Series A, B, B-1, C, D, E and F preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Sanderling Venture Partners V, LPVenture capitalnot statednot statedHeld Series A, B, B-1, C, D, E and F preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Sanderling Ventures Management VVenture capitalnot statednot statedHeld Series A, B, B-1, C, D, E and F preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Sanderling Ventures Management VIVenture capitalnot statednot statedHeld Series A, B, B-1, C, D, E and F preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Sanderling VI Beteiligungs GmbH & Co KGCompanynot statednot statedHeld Series A, B, B-1, C, D, E and F preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Sanderling VI Limited PartnershipFund or asset managernot statednot statedHeld Series A, B, B-1, C, D, E and F preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Sanderling V LTD PartnershipFund or asset managernot statednot statedHeld Series A, B, B-1, C, D, E and F preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Sanderling V Strategic Exit Fund LPFund or asset managernot statednot statedHeld Series A, B, B-1, C, D, E and F preferred stock, 10% owner (Form 3, 2013)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 21 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Chimerix Inc.
NameRoleNamed in
Heather W. Knight-TrentVice President of Regulatory AffairsJul 2019
Michael A. AlrutzSenior Vice President, General Counsel and Corporate SecretaryJul 2019
Mike AndrioleChief Business and Financial OfficerJul 2019
Mike ShermanChief Executive Officer and PresidentJul 2019
Odin W. NadererVice President, Clinical Pharmacology and Translational MedicineJul 2019
Randall A. LanierChief Science OfficerJul 2019
Roy W. WareChief Manufacturing and Technology OfficerJul 2019
W. Garrett NicholsChief Medical OfficerJul 2019
George I. Painter, Ph.DExecutive officerFeb 2011
Gwendolyn P. Painter, M.D., MPHExecutive officerFeb 2011
Kenneth I. MochExecutive officerFeb 2011
George Painter, Ph.D.Executive officerAug 2009
Merrick Almond, Ph.D.Executive officerAug 2009
Rosemary O'Mahony, Ph.D.Executive officerAug 2009
Catherine L. GillissDirectorJul 2019
Edward F. Greissing, Jr.DirectorJul 2019
Fred A. MiddletonDirectorJul 2019
James M. DalyDirectorJul 2019
Martha J. DemskiDirectorJul 2019
Mike ShermanChief Executive Officer and PresidentJul 2019
Patrick F. MachadoDirectorJul 2019
Robert J. MeyerDirectorJul 2019
Ronald C. Renaud, JrDirectorJul 2019
Arthur M. PappasDirectorFeb 2011
Farah P. ChampsiDirectorFeb 2011
George I. Painter, Ph.DDirectorFeb 2011
James M. NiedelDirectorFeb 2011
Kenneth I. MochDirectorFeb 2011
Seth A. Rudnick, M.D.DirectorFeb 2011
Timothy J. WollaegerDirectorFeb 2011
Edward E. Penhoet, Ph.D.DirectorAug 2009
George Painter, Ph.D.DirectorAug 2009
Graham K. Crooke, M.B.B.S.DirectorAug 2009

About

Company in Durham, United States.